Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 11/20 | 0.45 |
| ▸ | SLC6A4 | P31645 | 11/20 | 0.45 |
| ▸ | SLC6A3 | Q01959 | 8/20 | 0.45 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.39 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.39 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | HRH1 | P35367 | 1/20 | 0.35 |
| ▸ | HTR2C | P28335 | 2/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.35 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5995989 | 0.86 | SLC6A2 (0.44) | SLC6A2SLC6A4SLC6A3HRH1CYP2D6 | |
| SCHEMBL7280300 | 0.82 | ADRA2A (0.35) | SLC6A2SLC6A4SLC6A3ADRA2CADRA2A | |
| SCHEMBL5995472 | 0.79 | SLC6A2 (0.34) | SLC6A2SLC6A4SLC6A3HRH1HTR2C | |
| SCHEMBL5993827 | 0.77 | TDP1 (0.32) | SLC6A2SLC6A4SLC6A3CYP2D6 | |
| SCHEMBL6455895 | 0.76 | SLC6A2 (0.41) | SLC6A2SLC6A4SLC6A3ADRA2CKMT2A | |
| SCHEMBL25355557 | 0.68 | HTR2C (0.54) | SLC6A2SLC6A4SLC6A3ADRA2CKMT2A | |
| SCHEMBL28776903 | 0.68 | HTR2C (0.54) | SLC6A2SLC6A4SLC6A3ADRA2CKMT2A | |
| SCHEMBL1638122 | 0.68 | HTR2C (0.54) | SLC6A2SLC6A4SLC6A3ADRA2CKMT2A | |
| SCHEMBL6256715 | 0.67 | KMT2A (0.53) | ADRA2CADRA2AADRA2BKMT2AMTNR1A | |
| SCHEMBL6193610 | 0.67 | LMNA (0.52) | SLC6A2SLC6A4SLC6A3ADRA2CKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7026321-B2 | Substituted heterocyclic compounds | CV THERAPEUTICS, INC. (US) | 2006-04-11 | — | — | US | disclosed |
| US-20040186109-A1 | piperazine derivatives, e.g., (2R)-1-(2-methylbenzothiazol-5-yloxy)-3-[4-({5-[4-(trifluoromethyl)phenyl](4,5-dihydroisoxazol-3-yl)}methyl)piperazinyl]propan-2-ol; treating diabetes, arrhythmia, intermittent claudication, angina, congestive heart disease, and myocardial infarction | CV THERAPEUTICS, INC. | 2004-09-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040186109-A1 | piperazine derivatives, e.g., (2R)-1-(2-methylbenzothiazol-5-yloxy)-3-[4-({5-[4-(trifluoromethyl)phenyl](4,5-dihydroisoxazol-3-yl)}methyl)piperazinyl]propan-2-ol; treating diabetes, arrhythmia, intermittent claudication, angina, congestive heart disease, and myocardial infarction | KCNJ2, PPARA, PPARD | SLC6A2 4763/4885SLC6A4 4357/4885SLC6A3 4596/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.